2 weeks Ago By Defense World Staff
Commonwealth Equity Services LLC purchased a new position in Immunome, Inc. (NASDAQ:IMNM – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,017 shares of the company’s stock, valued at approximately $202,000.
A number of other large investors also recently modified their holdings of IMNM. Sequoia Financial Advisors LLC increased its holdings in Immunome by 11.7% during the 4th quarter.
Sequoia Financial Advisors LLC now owns 19,065 shares of the company’s stock worth $202,000 after acquiring an additional 2,000 shares during the period. AlphaQuest LLC increased its holdings in shares of Immunome by 786,700.0% in the fourth quarter.
AlphaQuest LLC now owns 7,868 shares of the company’s stock worth $84,000 after purchasing an additional 7,867 shares during the period. Raymond James Financial Inc. bought a new position in shares of Immunome in the fourth quarter worth $274,000.
Charles Schwab Investment Management Inc. raised its position in shares of Immunome by 3.3% in the fourth quarter.
Charles Schwab Investment Management Inc. now owns 457,252 shares of the company’s stock worth $4,856,000 after buying an additional 14,775 shares in the last quarter. Finally, Johnson Financial Group LLC bought a new stake in Immunome during the fourth quarter valued at $212,000.
44.58% of the stock is currently owned by institutional investors. Insider Transactions at ImmunomeIn related news, Director Jean Jacques Bienaime acquired 7,000 shares of the firm’s stock in a transaction on Monday, March 24th.
The stock was acquired at an average cost of $8.21 per share, for a total transaction of $57,470.00.
Following the acquisition, the director now owns 23,615 shares of the company’s stock, valued at $193,879.15. This trade represents a 42.
13 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Clay B.
Siegall bought 150,000 shares of the company’s stock in a transaction dated Friday, January 31st. The stock was bought at an average cost of $7.75 per share, with a total value of $1,162,500.
00. Following the completion of the transaction, the chief executive officer now owns 669,636 shares in the company, valued at approximately $5,189,679. This trade represents a 28.
87 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 306,400 shares of company stock worth $2,322,995.
8.60% of the stock is currently owned by insiders. Immunome Stock Down 0.
2 %Shares of Immunome stock opened at $6.20 on Friday. The company’s fifty day simple moving average is $8.
63 and its two-hundred day simple moving average is $10.65. Immunome, Inc.
has a 12-month low of $5.15 and a 12-month high of $21.72.
The firm has a market cap of $539.10 million, a PE ratio of -0.76 and a beta of 2.
05. Immunome (NASDAQ:IMNM – Get Free Report) last posted its earnings results on Wednesday, March 19th. The company reported ($0.
84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16).
Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%.
The business had revenue of $2.74 million during the quarter, compared to the consensus estimate of $3.07 million.
As a group, sell-side analysts expect that Immunome, Inc. will post -2.21 earnings per share for the current fiscal year.
Analyst Upgrades and DowngradesSeveral equities research analysts have issued reports on IMNM shares. Stephens reiterated an “overweight” rating and set a $30.00 target price on shares of Immunome in a research report on Thursday, March 20th.
Lifesci Capital assumed coverage on shares of Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price objective for the company.
Lake Street Capital initiated coverage on shares of Immunome in a research note on Wednesday, April 2nd. They issued a “buy” rating and a $23.00 price target for the company.
Guggenheim reduced their price objective on Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday, March 20th.
Finally, Wedbush reissued an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research note on Thursday, March 20th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.
com, the stock presently has an average rating of “Buy” and an average target price of $25.14.View Our Latest Analysis on ImmunomeAbout Immunome (Free Report)Immunome, Inc, a biotechnology company, develops targeted cancer therapies.
The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.Featured ArticlesFive stocks we like better than ImmunomeWhat is the S&P 500 and How It is Distinct from Other IndexesJoby Aviation: Operational Momentum vs. Market Sentiment3 Grocery Stocks That Can Help Take a Bite Out of Inflation Broadcom’s Big Outperformance Shows Strength Amid Tariff DeclineHow to Capture the Benefits of Dividend IncreasesCarvana: Can Turnaround Strength Outdrive Market Headwinds?Want to see what other hedge funds are holding IMNM? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Immunome, Inc. (NASDAQ:IMNM – Free Report)..
